S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,221.96 (+0.76%)
DOW   26,808.05 (+0.62%)
QQQ   260.47 (+0.03%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NYSE:IQVIqvia Stock Price, Forecast & News

$152.16
+4.26 (+2.88 %)
(As of 07/15/2020 02:38 PM ET)
Add
Compare
Today's Range
$149.26
Now: $152.16
$152.89
50-Day Range
$135.99
MA: $142.76
$153.06
52-Week Range
$81.79
Now: $152.16
$169.14
Volume504,222 shs
Average Volume1.60 million shs
Market Capitalization$29.06 billion
P/E Ratio138.33
Dividend YieldN/A
Beta1.32
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Read More
Iqvia logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.09 billion
Cash Flow$13.20 per share
Book Value$32.28 per share

Profitability

Net Income$191 million

Miscellaneous

Employees67,000
Market Cap$29.06 billion
Next Earnings Date7/22/2020 (Confirmed)
OptionableOptionable

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Iqvia (NYSE:IQV) Frequently Asked Questions

How has Iqvia's stock been impacted by COVID-19 (Coronavirus)?

Iqvia's stock was trading at $125.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IQV shares have increased by 21.3% and is now trading at $152.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iqvia?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

When is Iqvia's next earnings date?

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Iqvia.

How can I listen to Iqvia's earnings call?

Iqvia will be holding an earnings conference call on Wednesday, July 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) issued its earnings results on Tuesday, April, 28th. The medical research company reported $1.50 earnings per share for the quarter, beating analysts' consensus estimates of $1.48 by $0.02. The medical research company earned $2.75 billion during the quarter, compared to the consensus estimate of $2.74 billion. Iqvia had a net margin of 1.93% and a return on equity of 18.48%. Iqvia's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.53 EPS. View Iqvia's earnings history.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its second quarter earnings guidance on Tuesday, April, 28th. The company provided EPS guidance of $1.00 to $1.09 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.15. The company issued revenue guidance of $2.365 billion to $2.440 billion, compared to the consensus revenue estimate of $2.47 billion.

What price target have analysts set for IQV?

17 analysts have issued 12-month price objectives for Iqvia's stock. Their forecasts range from $110.00 to $195.00. On average, they anticipate Iqvia's stock price to reach $153.65 in the next twelve months. This suggests a possible upside of 1.0% from the stock's current price. View analysts' price targets for Iqvia.

Has Iqvia been receiving favorable news coverage?

News articles about IQV stock have been trending extremely negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near future. View the latest news about Iqvia.

Are investors shorting Iqvia?

Iqvia saw a drop in short interest in June. As of June 30th, there was short interest totaling 2,600,000 shares, a drop of 5.8% from the June 15th total of 2,760,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.4% of the company's stock are short sold. View Iqvia's Current Options Chain.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL) and Accenture (ACN).

Who are Iqvia's key executives?

Iqvia's management team includes the following people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are Iqvia's major shareholders?

Iqvia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.17%), Veracity Capital LLC (0.09%), DNB Asset Management AS (0.06%), McGuire Investment Group LLC (0.04%), Whittier Trust Co. (0.03%) and Wesbanco Bank Inc. (0.03%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View institutional ownership trends for Iqvia.

Which major investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, McGuire Investment Group LLC, IFM Investors Pty Ltd, Wesbanco Bank Inc., Chesley Taft & Associates LLC, CENTRAL TRUST Co, and Louisiana State Employees Retirement System. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, and Michael R Mcdonnell. View insider buying and selling activity for Iqvia.

Which major investors are buying Iqvia stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including Veracity Capital LLC, Envestnet Asset Management Inc., Gradient Investments LLC, Whittier Trust Co., DNB Asset Management AS, UNIVEST FINANCIAL Corp, Fulton Bank N. A., and First American Trust FSB. View insider buying and selling activity for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $152.16.

How big of a company is Iqvia?

Iqvia has a market capitalization of $29.06 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

What is Iqvia's official website?

The official website for Iqvia is www.iqvia.com.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.